Nancy B. Davis

2.4k total citations
61 papers, 989 citations indexed

About

Nancy B. Davis is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Nancy B. Davis has authored 61 papers receiving a total of 989 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pulmonary and Respiratory Medicine, 28 papers in Oncology and 24 papers in Surgery. Recurrent topics in Nancy B. Davis's work include Bladder and Urothelial Cancer Treatments (22 papers), Cancer Immunotherapy and Biomarkers (19 papers) and Renal cell carcinoma treatment (17 papers). Nancy B. Davis is often cited by papers focused on Bladder and Urothelial Cancer Treatments (22 papers), Cancer Immunotherapy and Biomarkers (19 papers) and Renal cell carcinoma treatment (17 papers). Nancy B. Davis collaborates with scholars based in United States, France and Canada. Nancy B. Davis's co-authors include Walter M. Stadler, Nicholas J. Vogelzang, Ronald C. Greene, Aude Fléchon, Christopher W. Ryan, Johann S. de Bono, Rajesh Bandekar, Axel Heidenreich, Éric Voog and David Taber and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

Nancy B. Davis

50 papers receiving 971 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nancy B. Davis United States	16	472	372	297	220	175	61	989
Diane Savarese United States	16	576 1.2×	526 1.4×	274 0.9×	218 1.0×	184 1.1×	24	1.2k
Metin Özkan Türkiye	16	507 1.1×	366 1.0×	182 0.6×	166 0.8×	168 1.0×	100	925
Kazuhiko Shibata Japan	15	916 1.9×	741 2.0×	226 0.8×	141 0.6×	215 1.2×	67	1.2k
Enzo Maria Ruggeri Italy	22	681 1.4×	535 1.4×	274 0.9×	354 1.6×	279 1.6×	103	1.4k
Wen-Qiong Xue China	16	437 0.9×	211 0.6×	615 2.1×	244 1.1×	415 2.4×	17	1.3k
Wen‐Wei Sung Taiwan	20	630 1.3×	371 1.0×	580 2.0×	232 1.1×	265 1.5×	91	1.5k
Aytuğ Üner Türkiye	15	400 0.8×	189 0.5×	131 0.4×	182 0.8×	105 0.6×	70	786
Luciano de Souza Viana Brazil	18	492 1.0×	396 1.1×	342 1.2×	137 0.6×	223 1.3×	37	968
Neal Osborn United States	12	680 1.4×	380 1.0×	517 1.7×	267 1.2×	361 2.1×	17	1.4k
Scott A. Kono United States	15	815 1.7×	674 1.8×	375 1.3×	485 2.2×	206 1.2×	22	1.4k

Countries citing papers authored by Nancy B. Davis

Since Specialization

Citations

This map shows the geographic impact of Nancy B. Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nancy B. Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nancy B. Davis more than expected).

Fields of papers citing papers by Nancy B. Davis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nancy B. Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nancy B. Davis. The network helps show where Nancy B. Davis may publish in the future.

Co-authorship network of co-authors of Nancy B. Davis

This figure shows the co-authorship network connecting the top 25 collaborators of Nancy B. Davis. A scholar is included among the top collaborators of Nancy B. Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nancy B. Davis. Nancy B. Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grivas, Petros, et al.. (2025). 3135eTiP INTerpath-011: Phase II study of intismeran autogene (V940/mRNA-4157) plus bacillus Calmette-Guérin (BCG) versus BCG alone for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC). Annals of Oncology. 36. S1515–S1515.

Davis, Nancy B., et al.. (2025). Nurses on Boards: Opportunities for Nurses to Share Their Knowledge, Critical Thinking, Experience, and Understanding of Health Care. Nephrology Nursing Journal. 52(1). 39–39.

Xu, Wenxin, Chelsea Nichols, Jason Hoppe, et al.. (2025). DNA damage repair alterations as predictive biomarker for platinum-based chemotherapy in metastatic urothelial cancer.. Journal of Clinical Oncology. 43(5_suppl). 853–853. 1 indexed citations

Fahey, Catherine C., Caroline A. Nebhan, Sally J. York, et al.. (2023). Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin. International Journal of Molecular Sciences. 24(22). 16109–16109. 11 indexed citations

Nizam, Amanda, Li Zhang, Omar Alhalabi, et al.. (2023). 2394P Biomarkers of treatment (Tx)-related toxicity in advanced urothelial carcinoma (aUC) pts treated with enfortumab vedotin (EV): Analysis of UNITE study. Annals of Oncology. 34. S1219–S1219. 3 indexed citations

Chen, Yu‐Wei, Matthew D. Tucker, Landon C. Brown, et al.. (2022). The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma. Cancers. 14(15). 3830–3830. 12 indexed citations

Tucker, Matthew D., Landon C. Brown, Yu‐Wei Chen, et al.. (2021). Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. Biomarker Research. 9(1). 80–80. 28 indexed citations

Koshkin, Vadim S., Yi Sun, Christopher Su, et al.. (2020). 771P Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancer. Annals of Oncology. 31. S594–S594. 2 indexed citations

Msaouel, Pavlos, Arlene O. Siefker‐Radtke, Randy F. Sweis, et al.. (2020). 705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC). Annals of Oncology. 31. S556–S556. 6 indexed citations

10.

Wood, Christopher G., James E. Ferguson, Joel S. Parker, et al.. (2020). Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. JCI Insight. 5(22). 19 indexed citations

11.

Milowsky, Matthew I., Nancy B. Davis, Chunkit Fung, et al.. (2020). 801TiP A phase II study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (ABATE). Annals of Oncology. 31. S607–S607. 2 indexed citations

12.

Ornstein, Moshe Chaim, Sumanta K. Pal, Laura S. Wood, et al.. (2019). Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. The Lancet Oncology. 20(10). 1386–1394. 78 indexed citations

13.

Fizazi, Karim, Johann S. de Bono, Aude Fléchon, et al.. (2011). Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. European Journal of Cancer. 48(1). 85–93. 158 indexed citations

14.

Lee, Richard T., Maha Hussain, Nancy B. Davis, et al.. (2008). A University of Chicago Consortium Phase II Trial of SB-715992 in Advanced Renal Cell Cancer. Clinical Genitourinary Cancer. 6(1). 21–24. 27 indexed citations

15.

Kroft, Steven H., et al.. (2008). Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma. Leukemia Research. 32(9). 1476–1479. 6 indexed citations

16.

Guralnick, Michael L., et al.. (2007). Quantifying the natural history of post-radical prostatectomy incontinence using objective pad test data. BMC Urology. 7(1). 2–2. 55 indexed citations

17.

Davis, Nancy B., et al.. (2006). Carcinoid tumors.. PubMed. 74(3). 429–34. 35 indexed citations

18.

Davis, Nancy B., Christopher W. Ryan, Walter M. Stadler, & Nicholas J. Vogelzang. (2005). A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. British Journal of Urology. 96(6). 787–790. 11 indexed citations

19.

Davis, Nancy B., et al.. (2002). Does Pc-Spes Interact With Warfarin?. The Journal of Urology. 167(4). 1793–1793. 9 indexed citations

20.

Davis, Nancy B.. (1987). Members of a winning team can empower nurses and brighten the future. AORN Journal. 45(6). 1261–1262.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact